Sugi Predict

Sugi Predict / Compounds / SCHEMBL2992126

SCHEMBL2992126

SCHEMBL2992126

CC(C)(C)OC(=O)N1CC(O)C(NC(=O)OCc2ccccc2)C1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 3/20 0.56
▸ PDE4B Q07343 1/20 0.49
▸ USP30 Q70CQ3 1/20 0.47
▸ CPB1 P15086 1/20 0.46
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ BACE1 P56817 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ STS P08842 1/20 0.43
▸ CTSL P07711 2/20 0.43
▸ SYK P43405 1/20 0.43
▸ NAMPT P43490 1/20 0.43
▸ CTSB P07858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3741626 1.00 CTSK (0.56) CTSKPDE4BUSP30CPB1MEN1
SCHEMBL19064067 1.00 CTSK (0.56) CTSKPDE4BUSP30CPB1MEN1
SCHEMBL2537459 1.00 CTSK (0.56) CTSKPDE4BUSP30CPB1MEN1
SCHEMBL765296 1.00 CTSK (0.56) CTSKPDE4BUSP30CPB1MEN1
SCHEMBL2534996 1.00 CTSK (0.56) CTSKPDE4BUSP30CPB1MEN1
SCHEMBL29187991 0.92 USP30 (0.49) CTSKPDE4BUSP30CPB1MEN1
SCHEMBL30158823 0.92 USP30 (0.49) CTSKPDE4BUSP30CPB1MEN1
SCHEMBL29187989 0.92 USP30 (0.49) CTSKPDE4BUSP30CPB1MEN1
SCHEMBL30411534 0.92 USP30 (0.49) CTSKPDE4BUSP30CPB1MEN1
SCHEMBL23938305 0.91 PDE4B (0.58) CTSKPDE4BUSP30MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4419525-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2025-07-23 — — EP disclosed
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2025-07-17 — — US disclosed
US-12312336-B2 Inhibitors of RAF kinases Pierre Fabre Médicament (FR) 2025-05-27 — — US disclosed
EP-4419525-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Artios Pharma Limited (GB) 2024-08-28 — — EP disclosed
CN-118556059-A Heterocyclic compounds for the treatment of cancer 阿提奥斯医药有限公司 2024-08-27 — — CN disclosed
WO-2023067353-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2023-04-27 — — WO disclosed
CN-115557946-A Heterocyclic lactam compound, pharmaceutical composition containing same and application thereof 四川科伦博泰生物医药股份有限公司 2023-01-03 — — CN disclosed
CN-114845711-A Inhibitors of RAF kinase 金耐特生物制药公司 2022-08-02 — — CN disclosed
EP-3400228-B1 FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF TABOMEDEX BIOSCIENCES INC (US) 2022-04-13 — — EP disclosed
US-20210300904-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2021-09-30 — — US disclosed
US-8889704-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2014-11-18 — — US disclosed
US-20140005213-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-01-02 — — US disclosed
EP-2678329-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS Array Biopharma, Inc. (US) 2014-01-01 — — EP disclosed
WO-2012154274-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2012-11-15 — — WO disclosed
US-7777032-B2 N-4-[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-N6-(3-ethyl-oxazolidin-2-ylidene)-quinazoline-4,6-diamine; use as type I receptor tyrosine kinase inhibitor; hyperproliferation diseases such as cancer; antiinflammatory agents ARRAY BIOPHARMA INC. (US) 2010-08-17 — — US disclosed
US-20090270621-A1 QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA, INC. (US) 2009-10-29 — — US disclosed
US-7585975-B2 Quinazoline analogs as receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2009-09-08 — — US disclosed
US-7501427-B2 Quinazoline analogs as receptor tyrosine kinase inhibitors ARRAY BIOPHARMA, INC. (US) 2009-03-10 — — US disclosed
US-20080194558-A1 Quinazoline analogs as receptor Tyrosine Kinase inhibitors ARRAY BIOPHARM, INC. (US) 2008-08-14 — — US disclosed
US-20050101616-A1 Quinazoline analogs as receptor tyrosine kinase inhibitors ARRAY BIOPHARMA, INC. 2005-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194558-A1 Quinazoline analogs as receptor Tyrosine Kinase inhibitors ABL1, ERBB2, FLT3 CTSK 2041/4885PDE4B 2655/4885USP30 3812/4885
US-20140005213-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 CTSK 3181/4885PDE4B 2617/4885USP30 2833/4885
US-20210300904-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF CTSK 1134/4885PDE4B 2435/4885USP30 1865/4885
US-20050101616-A1 Quinazoline analogs as receptor tyrosine kinase inhibitors ABL1, ERBB2, FLT3 CTSK 2041/4885PDE4B 2655/4885USP30 3812/4885
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER NQO1, VHL, SDHA CTSK 1668/4885PDE4B 1784/4885USP30 3588/4885
US-12312336-B2 Inhibitors of RAF kinases BRAF, RAF1, ARAF CTSK 1134/4885PDE4B 2435/4885USP30 1865/4885
US-20090270621-A1 QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS ABL1, ERBB2, FLT3 CTSK 2041/4885PDE4B 2655/4885USP30 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.